[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2032

Conditions
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate CarcinomaHormone Sensitive Prostate Cancer
Interventions
DRUG

[Ac-225]-PSMA-62 (mCRPC)

"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."

DRUG

[Ac-225]-PSMA-62 (OmHSPC)

"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."

Trial Locations (7)

L8V 5C2

NOT_YET_RECRUITING

Juravinski, Hamilton

H3T 1E2

NOT_YET_RECRUITING

Jewish General Hospital, Montreal

H4A 3J1

RECRUITING

McGill University, Montreal

G1J 1Z4

RECRUITING

Centre Hospitalier Universite de QUEBEC, Québec

G7H 5H6

NOT_YET_RECRUITING

Hopital De Chicoutimi, Saguenay

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

V5Z4E6

RECRUITING

BC Cancer Vancouver, Vancouver

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY